Opioid | Jotup

Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain

Retrieved on:

Monday, November 4, 2019

The study objectives were to evaluate the effect of OMIDRIA compared to epinephrine on perioperative fentanyl use and pain in patients undergoing cataract surgery.

Key Points:

The study objectives were to evaluate the effect of OMIDRIA compared to epinephrine on perioperative fentanyl use and pain in patients undergoing cataract surgery.
Sixty patients were prospectively assigned to have either OMIDRIA (41 patients) or epinephrine (19 patients) added to the irrigation solution used during surgery.
Our study found that OMIDRIA cut intraoperative pain scores in half while markedly reducing the need for fentanyl during cataract surgery, said Dr. Donnenfeld.
With the publication of the Donnenfeld opioid-sparing data, Omeros believes that OMIDRIA meets all of CMS requirements for the non-opioid exclusion.

Award-Winning Precision Medicine Executives Launch New AI Technology Platform Bennufit™ Health to Solve Dueling Public Health Crises of Chronic Pain and Opioid Abuse

Retrieved on:

Wednesday, October 30, 2019

RTT, Opioid use disorder, Substance dependence, Opioid, Reproductive health

Bennufit has been incubated by social entrepreneurship fund, Profound Ventures, of Newport Beach, California.

Key Points:

Bennufit has been incubated by social entrepreneurship fund, Profound Ventures, of Newport Beach, California.
Laura Hunter, Esq., a Founding Partner of Profound Ventures, explains "With chronic pain as the world's most prevalent and expensive health condition, and opioid abuse being the nation's largest cause of preventable death, Profound Ventures is committed to funding and supporting new technologies that solve profound societal problems.
Bennufit is one of the socially-responsible companies we support.
We look forward to collaborating with the FDA, payers, health systems and others on helping solve these dueling public health crises."

Opioids Market to Reach $22.38 Bn by 2026, Globally, at 3.2% CAGR, Says Allied Market Research

Retrieved on:

Wednesday, October 30, 2019

Morphine, Opioid, Pain management

The report provides a detailed analysis of the market, including key winning strategies, industry drivers & restraints, market size & forecast, top investment pockets, competitive landscape, and wavering market trends.

Key Points:

The report provides a detailed analysis of the market, including key winning strategies, industry drivers & restraints, market size & forecast, top investment pockets, competitive landscape, and wavering market trends.
Rise in use of opioids in pain management fuels the growth of the global opioids market.
Nevertheless, increase in consumption of opioids in developing economies is projected to create a number of opportunities in the industry.
Based on application, the pain management segment garnered the major share in 2018, holding nearly three-fifths of the global opioids market.

Opioids Market to Reach $22.38 Bn by 2026, Globally, at 3.2% CAGR, Says Allied Market Research

Retrieved on:

Wednesday, October 30, 2019

Morphine, Opioid, Pain management

The report provides a detailed analysis of the market, including key winning strategies, industry drivers & restraints, market size & forecast, top investment pockets, competitive landscape, and wavering market trends.

Key Points:

The report provides a detailed analysis of the market, including key winning strategies, industry drivers & restraints, market size & forecast, top investment pockets, competitive landscape, and wavering market trends.
Rise in use of opioids in pain management fuels the growth of the global opioids market.
Nevertheless, increase in consumption of opioids in developing economies is projected to create a number of opportunities in the industry.
Based on application, the pain management segment garnered the major share in 2018, holding nearly three-fifths of the global opioids market.

BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019

Retrieved on:

Wednesday, October 30, 2019

Medicine, Perception, Clinical medicine, Pain, RTT, Cancer pain, Oncology, Substance dependence, Chronic condition, Opioid, Chronic pain

BioDelivery Sciences International, Inc.(NASDAQ: BDSI) is a specialty pharmaceutical company dedicated to patients living with chronic conditions.

Key Points:

BioDelivery Sciences International, Inc.(NASDAQ: BDSI) is a specialty pharmaceutical company dedicated to patients living with chronic conditions.
BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence.
For more information, please visit us https://bdsi.com or follow us on Facebook or Twitter BDSI @BioDeliverySI .

Groundbreaking Opioid Settlement Reached with Opioid Manufacturer and National Opioid Distributors

Retrieved on:

Friday, October 25, 2019

Psychoactive drugs, Morphine, RTT, Morphinans, Drugs, Euphoriants, Opioid, Neonatal withdrawal, Heroin, Shibley

Peter Weinberger of Spangenberg Shibley & Liber LLP served as trial counsel for the trial representing two Ohio counties against five Big Pharma defendants for damages brought on by the opioid epidemic.

Key Points:

Peter Weinberger of Spangenberg Shibley & Liber LLP served as trial counsel for the trial representing two Ohio counties against five Big Pharma defendants for damages brought on by the opioid epidemic.
"This settlement will have an immediate impact on funding county programs designed to abate the opioid epidemic.
It will treat babies exposed to opioids during pregnancy who are born with neonatal abstinence syndrome," Mr. Weinberger said.
To learn more about this settlement contact us at Spangenberg Shibley & Liber LLP by visiting spanglaw.com.

Statement from Acting FDA Commissioner Ned Sharpless, M.D., on agency's first year accomplishments implementing SUPPORT Act authorities to address the opioids crisis

Retrieved on:

Thursday, October 24, 2019

Psychoactive drugs, RTT, Food and Drug Administration, United States Public Health Service, Health, Opioid, United States Department of Health and Human Services, Euphoriants, Calcium channel blockers, Scott Gottlieb, Opioid epidemic in the United States

This can reduce patient exposure to opioids as well as the number of leftover opioids available for abuse or misuse in the community.

Key Points:

This can reduce patient exposure to opioids as well as the number of leftover opioids available for abuse or misuse in the community.
The guidance makes clear that the FDA considers the broader public health effects of these products as part of its benefit-risk assessment.
Strengthening FDA and U.S. Customs and Border Protection (CBP) coordination and capacity (Section 3014): The FDA, in coordination with CBP and the U.S.
Additionally, with the authorities provided by the SUPPORT Act, the FDA is taking new steps to promote the development of drugs to treat pain that are not addictive.

PAINWeekEnd in Charleston, South Carolina, Offers CE/CME Education to Address the Opioid Abuse Public Health Crisis

Retrieved on:

Thursday, October 24, 2019

Morphine, Psychoactive drugs, Palliative care, RTT, Drugs, Pain, Euphoriants, Acute pain, Pain management, Opioid, Heroin

Charleston County, South Carolina, had the 3rd highest amount of pain medications dispensed in the entire country from 2006 to 2012.

Key Points:

Charleston County, South Carolina, had the 3rd highest amount of pain medications dispensed in the entire country from 2006 to 2012.
During that span, South Carolina dispensed almost 2 billion opioid pills.
Where do healthcare professionals even begin to attempt to improve patient care, and ultimately save lives?
At PAINWeekEnd, faculty member Mark Garofoli, PharmD, MBA, BCGP, CPE, will present Pain Management at Ground Zero.

The National Safety Council Creates Opioids at Work Toolkit to Help Employers Reduce the Impact of Opioids in the Workplace

Retrieved on:

Thursday, October 24, 2019

Morphine, Opioid, Workplace

The employer toolkit features sample policies, fact sheets, presentations, safety talks, posters, white papers, reports, videos and more, to guide employers in the implementation of workplace opioids programs.

Key Points:

The employer toolkit features sample policies, fact sheets, presentations, safety talks, posters, white papers, reports, videos and more, to guide employers in the implementation of workplace opioids programs.
"The Opioids at Work Employer Toolkit is designed to help employers understand how opioids impact the workplace, recognize signs of impairment, educate employees on the risks of opioid use, develop drug-related HR policies and support employees who are struggling with opioid misuse."
The Opioids at Work Employer Toolkit is organized into several key subject matter areas, including the Basics, Human Resources, Safety Professionals, Supervisors, Employee Education and Other Resources.
Visit the National Safety Council's Opioids at Work Employer Toolkit website to access additional information, extensive materials and other employer resources.

Kroger and Cardinal Health Foundation to Host Drug Take Back Events across 25 States on October 26

Retrieved on:

Tuesday, October 22, 2019

Health, Morphine, Psychoactive drugs, RTT, Kroger, Prescription drug, Opioid, Heroin

"Kroger is committed to being a part of the solution to combat America's opioid and prescription drug misuse epidemic.

Key Points:

"Kroger is committed to being a part of the solution to combat America's opioid and prescription drug misuse epidemic.
"Safe disposal is one of the key medication safety messages of our Generation Rx programand the Cardinal Health Foundation is pleased to again join Kroger in hosting drug take back events."
The Cardinal Health Foundation has partnered with Kroger in hosting drug take back events across America for several years.
To view the list of Kroger and Cardinal Health Foundation's participating drug take back locations, visit Kroger.com .